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Abstract The predominance of oxidative stress in many tu-
mour cell environments provides a means to selectively target
these cells via protein oxidation. The zinc ¢ngers of transcrip-
tion factors utilise cysteine thiols for structural zinc coordina-
tion. Redox control of DNA binding regulates transcription and
therefore the overall rates of proliferation, apoptosis and ne-
crosis in the carcinoma. We report here the adverse e¡ects of
glutathione peroxidase (GPx) mimics towards zinc ¢nger motifs
and PC12 cell survival. Nanomolar catalyst concentrations fa-
cilitated H2O2-induced oxidation of an Sp1 transcription factor
fragment. In PC12 cells GPx catalysis triggered a signi¢cant
increase in cell death, correlating with severity of oxidative
stress. As a consequence, we conclude that GPx mimics are
potential chemotherapeutic agents.
/ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
Key words: Oxidative stress; Redox catalysis;
Glutathione peroxidase mimic; Zinc ¢nger protein; PC12 cell
1. Introduction
Cellular production and removal of reactive oxygen species
(ROS) need to strike a critical balance and as such the cell
employs several antioxidant systems that e¡ectively quench
and neutralise these toxic molecules. In contrast, a host of
human disorders, ranging from in£ammatory and neurode-
generative to viral and proliferative diseases, are associated
with oxidative stress, a biochemical condition where the pro-
duction of ROS is increased while antioxidant defence is de-
creased [1,2]. A raised level of ROS has also been observed in
certain animal and human cancer cells [3,4] and it has been
shown that antioxidant enzyme levels in these cells are low.
For example, human kidney, prostate and six forms of human
lung carcinomas have lower antioxidant enzyme staining lev-
els [5,6].
A disturbed redox environment could be exploited to spe-
ci¢cally attack these types of cancer cells whilst leaving cells
with a healthy redox balance una¡ected. Fernandez-Pol et al.
have recently suggested that agents which can regulate the
zinc ¢nger structure of transcription factors (e.g. Sp1) and
hence in£uence DNA interactions have the potential to con-
trol viral and cancerous diseases [7]. While these authors have
proposed the use of zinc-chelating agents to attack the zinc^
sulfur complex, oxidation of the thiol ligands might be the
more promising approach [8]. ROS rapidly oxidise and sub-
sequently inactivate redox-sensitive proteins, severely damag-
ing membranes and DNA. Theoretically, it should be possible
to catalyse the oxidation of the zinc ¢nger, preventing DNA
binding, transcription, protein synthesis and proliferation and
hence induce tumour cell death without excessive use of oxi-
dants or chelators. Since redox-sensitive targets and ROS are
already present in these cells, but do not rapidly react with
each other, a redox catalyst merely facilitating a hindered ox-
idation process would dramatically sensitise these cells to al-
ready existing ‘internal’ oxidative stressors by promoting their
reaction with zinc ¢nger and other thiol dependent proteins.
The selenoenzyme glutathione peroxidase (GPx) catalyses
the reaction of peroxides or peroxynitrite with glutathione
(GSH), reducing the oxidative stressor with concomitant for-
mation of oxidised glutathione. Catalytic antioxidants that
mimic the action of GPx can be formed synthetically by plac-
ing a selenium or tellurium atom in an organic framework.
These mimics can undergo the same reaction cycle as GPx,
but lack the enzyme’s substrate speci¢city and are able to
accept any cellular thiol. As such they can function as either
pro-oxidants or antioxidants, depending upon the cellular re-
dox state.
This paper demonstrates the ability of nanomolar concen-
trations of redox catalysts to dramatically increase the dam-
aging e¡ects of the ROS hydrogen peroxide on a zinc ¢nger
protein Sp1 fragment. The most active compound sensitised
cultured PC12 neuronal cancer cells to the e¡ects of H2O2.
The activity of this agent is the result of a synergistic e¡ect of
peroxide with catalyst as the latter was non-toxic in the ab-
sence of oxidative stress conditions.
2. Materials and methods
2.1. Materials
The zinc ¢nger peptide fragment resembling the zinc ¢nger of tran-
scription factor Sp1 KFACPECPKRFMRSDHLSKHIKTHQNKK
[9] (ZFPF) was ordered from the Peptide Synthesis Unit IBMS (Uni-
versity of Southampton, Southampton, UK). All chemicals required
for electrochemistry, in vitro zinc ¢nger assay, atomic absorption and
cell culture were either analytical or tissue culture grade and pur-
chased from Sigma-Aldrich Company (Poole, UK). Redox catalysts
were synthesised as described previously [10]. Rat adrenal PC12 cell
lines were purchased from ECACC (Salisbury, UK). Chelexed (i.e.
‘metal free’) nitrogen-purged bu¡ers were used for the ZFPF oxida-
tion assay. All experiments were performed in at least triplicate and
results are given as means.
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2.2. Methods
The zinc form of ZFPF (Zn1-ZFPF, molecular weight= 3396 Da)
was prepared according to an established metal-incorporation proce-
dure [11]. The concentration of peptide was determined by parallel
measurement of thiol (spectrophotometric 2,2P-dithiodipyridine assay)
and amino content (spectrophotometric ninhydrin assay). The number
of zinc ions bound per ZFPF was determined by atomic absorption
spectroscopy. Cyclic voltammetry was performed on a 100 B/W work-
station (BAS, Chichester, UK). Voltammograms of organochalcogens
(50^100 WM) were recorded as previously described [10].
For the ZFPF stability assays, Zn1-ZFPF (5 WM) and H2O2 (250
WM) were incubated in the presence of varying concentrations of
catalyst in Tris^HCl (20 mM, pH 7.4) at 37‡C for 10 min. The reac-
tion was terminated by a 2-min incubation with catalase to remove
excess H2O2. 5,5P-Dithiobis(2-nitrobenzoic acid) (DTNB) was added
(100 WM ¢nal concentration) and the reaction of the remaining ZFPF
thiols was monitored at 412 nm (O412 = 13 600 M31 cm31) using a UV/
VIS spectrophotometer.
For the cell survival assays, rat adrenal PC12 cells were cultured in
RPMI 1640 suspension according to Kearns et al. [12], supplemented
with glutamine (2 mM) and gentamicin (250 U/ml). Cells were fed
three times a week and subcultured every 7 days. For experimenta-
tion, undi¡erentiated cells were plated at 100 000 cells (100 Wl) per well
and pre-incubated for 1 h with test compounds (see Table 1: 10 WM)
at 37‡C and 5% CO2, in a Sanyo CO2 incubator, followed by addition
of varying concentrations of H2O2 (50^500 WM) and overnight incu-
bation. A H2O2 dose^response curve in the absence of test com-
pounds and a ‘catalyst only’ incubation at the highest catalyst con-
centration used were established as controls. The e¡ect of H2O2 (200
WM) on the standard GPx mimic ebselen (2-phenyl-1,2-benzisoselena-
zol-3(2H)-one, 10 WM) was also examined. Cell viability was measured
using the standard MTT assay [13] and a Dynex technologies MRX
microplate reader. Individual treatments consisted of six wells per
experiment and experiments were replicated at least four times.
3. Results
3.1. Catalysis of zinc ¢nger oxidation by a selection of
organochalcogens
Hydrogen peroxide decreased the thiol concentration in the
ZFPF sample indicating oxidation of the peptide. In the ab-
sence of additional redox agents, hydrogen peroxide (250 WM)
oxidised 7% of the ZFPF (10 WM) thiols within 10 min. The
presence of GPx mimics dramatically increased this oxidative
e¡ect of H2O2. Table 1 shows the IC50 values for a range of
telluride and selenide catalysts obtained for the oxidation of
the Sp1 zinc ¢nger peptide in the presence of peroxide. Con-
trol experiments included incubations with methanol, H2O2
alone, and catalyst in the absence of H2O2, all of which had
negligible e¡ects on the measurements. Among the chalcogens
tested, diselenides and both mono- and ditellurides dramati-
cally enhanced the peroxide driven oxidation of ZFPF thiols,
indicating that these agents are good thiol peroxidation redox
catalysts in vitro. The monoselenide 1 and ebselen were sig-
ni¢cantly less active.
All of the chalcogen species assayed were redox active in the
range of +300 to +1200 mV against the standard silver elec-
trode. The tellurides possessed lower Epa values from +300 to
+650 mV and the selenides were more resistant to oxidation
with Epa values ranging from +700 to +1200 mV. Mono-
chalcogens had a lower Epa, by approximately 225 mV,
than their corresponding dichalcogens, as can be seen by a
comparison of the analogous structures 1, 4, 6 and 7. There
was a general trend that compounds with a low oxidation
potential, i.e. that are easier to oxidise, have a higher activity
in the ZFPF assay (i.e. lower IC50 values) with an interesting
correlation between the dichalcogenides (2^4, 7, 8, R2 = 0.77).
All of these compounds possessed one irreversible oxidation
potential with the exception of 5, which was unique in that it
had several oxidation peaks, exhibited reversible electron-
transfer behaviour at a relatively low potential (Epa=+299
and +821 mV, Epc=+255 and +763 mV) and was also the
most e¡ective redox catalyst, possessing the lowest IC50 value
(16 nM). Cell culture studies have therefore focused on this
versatile redox catalyst.
3.2. Catalysis of cancer cell death
PC12 cells were challenged by H2O2 to simulate the con-
ditions of oxidative stress prevalent in malignant tumours [4].
Fig. 1 shows that increasing levels of the oxidative stressor
Table 1
Correlation between the oxidative capacity (IC50) of compounds 1^8
and Epa
The cyclic voltammograms were recorded at a scan rate of 200 mV/
s. For the in vitro experiments, the Zn1-ZnF (5 WM) was incubated
with catalysts (nM range) and H2O2 (250 WM) in Tris^HCl (20
mM, pH 7.4) at 37‡C for 10 min. Catalase (1 nM), followed by
DTNB (100 WM), was added to the mixture and the formation of
TNB3 measured at 412 nm.
Experimental error 10% (n=3).
*Literature value [10].
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Fig. 1. E¡ect of monochalcogen 5 and H2O2 on PC12 cell survival.
PC12 cells were treated with increasing concentrations of H2O2 only
(50^500 WM, F) and the experiment repeated in the presence of 5
(10 WM, a). After an overnight incubation the % cell survival was
measured using the MTT assay [13].
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hydrogen peroxide reduce cell survival. This e¡ect of peroxide
is considerably enhanced by a physiologically relevant dosage
of 5 (10 WM), which in the absence of H2O2 has no toxic e¡ect
on PC12 cells. A signi¢cant e¡ect was observed even at the
lowest concentration of H2O2 (50 WM) used in the study. Fig.
2 is a representation of the non-toxic nature of compound 5 in
the absence of H2O2 and also shows the non-toxicity and
inactivity of the standard drug ebselen, corresponding to its
lower in vitro IC50 of 110 nM. The 2% methanol control had
no e¡ect on cell survival.
4. Discussion
The results obtained in the in vitro experiments indicate
that chalcogen-based GPx mimics are e¡ective redox catalysts.
These agents enhance the (per)oxidation of thiols in the pres-
ence of the oxidative stressor hydrogen peroxide [14]. While
GPx is rather speci¢c for GSH thiols, an advantage in pro-
oxidant therapy is that synthetic mimics lack this substrate
speci¢city and can be used to attack zinc/sulfur complexes
such as the zinc ¢nger ZFPF. Oxidation of ZFPF has impor-
tant biochemical implications. The mRNA levels and DNA-
binding capacity of Sp1 increase in epithelial tumours [15] and
Sp1 has also been implicated in lung cancer [16]. Catalysts,
using the ZFPF of Sp1 ^ or indeed other redox-sensitive pro-
teins [17] ^ as a target, therefore have the potential to destroy
this ¢nger (and similar redox-sensitive thiol proteins) in vivo
and ultimately shut down cells with impaired redox balance,
such as epithelial and lung cancer cells.
On the other hand, redox catalysts ‘only’ facilitate redox
reactions under the control of an already existing cellular re-
dox balance. These agents do not themselves change this bal-
ance and their activity is therefore determined by the environ-
ment in which they are placed. GPx mimics could therefore be
considered as redox sensors, being able to distinguish on
grounds of oxidative stress. If these assumptions were correct,
catalysts should greatly potentiate the e¡ects of already exist-
ing stressors but should not be toxic on their own.
The results obtained in cell culture clearly support our ini-
tial hypothesis. The cell culture activity of compound 5 is not
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Fig. 2. Cytotoxicity and pro-oxidant e¡ects of ebselen and 5. PC12 cell viability was determined by the MTT assay in the absence ( ) and pres-
ence (F) of H2O2 (200 WM) after an overnight incubation. The pro-oxidant e¡ects of ebselen (10 WM) and 5 (10 WM) were established under
these conditions.
Fig. 3. Hypothetical catalytic cycles for GPx mimic 5. 5 can be oxidised by hydrogen peroxide to form the telluroxide, which is then reduced
by ZFPF, regenerating the telluride. Oxidation of ZFPF results in zinc ejection due to the formation of the disul¢de. 5 may also operate via
an alternative redox path, forming the telluroketone upon oxidation by hydrogen peroxide, which is then reduced by ZFPF.
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intrinsic to the compound itself, but is generated as a syner-
gistic e¡ect of the peroxide/catalyst interaction. These ¢ndings
make GPx-like catalysts a distinct class of potential drugs that
are di¡erent from ‘continuously active’ agents and ‘triggered’,
suicide agents (which once activated are permanently active).
As it has been established that antioxidant levels in certain
human and animal cancer cells are low, it might be possible to
use this particular cellular redox state, in conjunction with
redox catalysts, to speci¢cally promote cancer cell death.
We have previously shown that there is a relationship be-
tween electrochemical potential and chemical structure, which
we have used to predict redox activity against the zinc/sulfur
protein MT [10]. The mechanism of GPx mimics is considered
to consist of chalcogen atom oxidation by ROS, followed by
reduction by cellular thiols. In the case of 5, the possibility of
additional redox mechanisms, possibly involving a conju-
gated, quinone-like oxidised species (Fig. 3), might explain
its exceptional catalytic activity. The elucidation of the precise
mode of action of these redox agents in malignant cells is the
subject of ongoing investigation.
In summary, these preliminary studies have investigated the
use of novel organochalcogen catalysts as possible anti-cancer
agents. Interestingly, the mechanism of action of these cata-
lysts depends on their environment, as they have the possibil-
ity to function as antioxidant catalysts in normal cells [10] and
pro-oxidants in cells exposed to oxidative stress. If these
agents are also able to adjust their activity in response to their
redox environment in vivo, they might provide access to an
important category of drugs. While this work has focussed on
cancer cells with a disturbed redox balance, similar conditions
are also present during infection and in£ammation. In addi-
tion, agents similar to 5 could be used to attack entities with a
disturbed redox balance while protecting healthy cells in their
role as antioxidants.
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